MRNA vs. TMO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MRNA and TMO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MRNA | TMO |
|---|---|---|
| Company Name | Moderna, Inc. | Thermo Fisher Scientific Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 10.46 billion USD | 183.06 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | December 7, 2018 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MRNA and TMO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MRNA | TMO |
|---|---|---|
| 5-Day Price Return | 1.05% | 6.61% |
| 13-Week Price Return | 4.63% | 12.07% |
| 26-Week Price Return | -19.99% | -15.35% |
| 52-Week Price Return | -66.92% | -19.08% |
| Month-to-Date Return | -9.03% | 3.66% |
| Year-to-Date Return | -35.33% | -6.81% |
| 10-Day Avg. Volume | 9.93M | 2.18M |
| 3-Month Avg. Volume | 10.26M | 2.89M |
| 3-Month Volatility | 56.65% | 37.87% |
| Beta | 2.04 | 0.78 |
Profitability
Return on Equity (TTM)
MRNA
-27.46%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
TMO
13.27%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, TMO’s Return on Equity of 13.27% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
MRNA
-94.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
TMO
15.23%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
TMO’s Net Profit Margin of 15.23% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
MRNA
-106.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
TMO
17.13%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
TMO’s Operating Profit Margin of 17.13% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | MRNA | TMO |
|---|---|---|
| Return on Equity (TTM) | -27.46% | 13.27% |
| Return on Assets (TTM) | -21.24% | 6.62% |
| Net Profit Margin (TTM) | -94.31% | 15.23% |
| Operating Profit Margin (TTM) | -106.34% | 17.13% |
| Gross Profit Margin (TTM) | 68.32% | 41.34% |
Financial Strength
Current Ratio (MRQ)
MRNA
3.93
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
TMO
1.93
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
TMO’s Current Ratio of 1.93 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MRNA
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TMO
0.70
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
TMO’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for MRNA is currently unavailable.
TMO
23.55
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
TMO’s Interest Coverage Ratio of 23.55 is in the upper quartile for the Life Sciences Tools & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | MRNA | TMO |
|---|---|---|
| Current Ratio (MRQ) | 3.93 | 1.93 |
| Quick Ratio (MRQ) | 3.59 | 1.50 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.70 |
| Interest Coverage Ratio (TTM) | -- | 23.55 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TMO
0.33%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
TMO’s Dividend Yield of 0.33% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TMO
9.27%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
TMO’s Dividend Payout Ratio of 9.27% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | MRNA | TMO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.33% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.27% |
Valuation
Price-to-Earnings Ratio (TTM)
MRNA
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MRNA is currently unavailable.
TMO
27.78
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
TMO’s P/E Ratio of 27.78 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
MRNA
3.42
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.42 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
TMO
4.23
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
TMO’s P/S Ratio of 4.23 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
MRNA
1.14
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
TMO
3.03
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
TMO’s P/B Ratio of 3.03 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | MRNA | TMO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 27.78 |
| Price-to-Sales Ratio (TTM) | 3.42 | 4.23 |
| Price-to-Book Ratio (MRQ) | 1.14 | 3.03 |
| Price-to-Free Cash Flow Ratio (TTM) | 34.70 | 29.63 |